President and CEO J. Robert Hurley is now also interim Diagnostic Division President, while Scott Atkins was named president of the Life Science Division.
The company said that it anticipates regulatory approval from the European Commission on or about June 16 and to close the acquisition by the end of the month.
The company's Clinical Diagnostics segment was up 3 percent year over year, while Life Science slid 11 percent.
The trials will evaluate biomarker panels for lung, colon, and prostate cancer, and may include a comparison of proteomics-based lung cancer tests from Somalogic and Celera.
The deadline for the deal has been pushed back to April 27 from March 23.
In a research note, Jon Groberg wrote that in the near term firms with a larger consumables presence in Japan face greater revenue risk, while instrument firms face greater mid-term risk.
The firms have said they expect to complete the transaction in the first half of this year.
Robert Friel today denied a report that the company is seeking a buyer after failing to land Beckman Coulter.
Shares of PerkinElmer climbed more than 9 percent on Thursday after a report was published saying that the firm is exploring being bought out amid a failed bid to acquire Beckman Coulter.
The company, which is being purchased by Danaher, did not report its earnings for the fourth quarter, but based on what it had previously reported for the first three quarters, revenues for the final quarter of 2010 were $986.5 million.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.